Beyond market averages, investors looking for exceptional returns turn to stock picking. Skillful choices in individual stocks have the power to substantially increase your wealth.
The closing price of Syndax Pharmaceuticals Inc (NASDAQ: SNDX) was $9.93 for the day, up 0.81% from the previous closing price of $9.85. In other words, the price has increased by $0.81 from its previous closing price. On the day, 2.72 million shares were traded.
Ratios:
Our analysis of SNDX’s different ratios will help us gain a deeper understanding of the company. For the most recent quarter (mrq), Quick Ratio is recorded 5.75 and its Current Ratio is at 5.80. In the meantime, Its Debt-to-Equity ratio is 1.61 whereas as Long-Term Debt/Eq ratio is at 1.54.
Upgrades & Downgrades
In addition, analysts’ ratings and any changes thereto give investors an idea of the stock’s future direction. In the most recent recommendation for this company, UBS on October 24, 2024, initiated with a Buy rating and assigned the stock a target price of $37.
On June 28, 2024, Jefferies started tracking the stock assigning a Buy rating and target price of $37.
Scotiabank Downgraded its Sector Outperform to Sector Perform on January 31, 2024, whereas the target price for the stock was revised from $36 to $23.
Insider Transactions:
Also, insider trades can serve as a great indicator of what management thinks about the future direction of a stock’s price. A recent insider transaction in this stock occurred on May 16 ’25 when Botwood Nicholas A.J. bought 11,765 shares for $8.99 per share. The transaction valued at 105,826 led to the insider holds 35,165 shares of the business.
Huber Martin H. Jr. bought 5,000 shares of SNDX for $44,950 on May 19 ’25. The Director now owns 79,000 shares after completing the transaction at $8.99 per share. On May 19 ’25, another insider, Katkin Keith, who serves as the Director of the company, bought 10,000 shares for $9.11 each. As a result, the insider paid 91,120 and bolstered with 100,000 shares of the company.
Valuation Measures:
For the stock, the TTM Price-to-Sale (P/S) ratio is 19.54 while its Price-to-Book (P/B) ratio in mrq is 3.97.
Stock Price History:
Over the past 52 weeks, SNDX has reached a high of $25.07, while it has fallen to a 52-week low of $8.58. The 50-Day Moving Average of the stock is -16.32%, while the 200-Day Moving Average is calculated to be -36.08%.
Shares Statistics:
A total of 86.05M shares are outstanding, with a floating share count of 82.47M. Insiders hold about 4.16% of the company’s shares, while institutions hold 115.49% stake in the company.
Earnings Estimates
The performance of Syndax Pharmaceuticals Inc (SNDX) in the stock market is under the watchful eye of 10.0 analysts actively contributing to its current rating.The consensus estimate for the next quarter is -$0.91, with high estimates of -$0.72 and low estimates of -$1.07.
Analysts are recommending an EPS of between -$3.22 and -$4.15 for the fiscal current year, implying an average EPS of -$3.71. EPS for the following year is -$2.58, with 10.0 analysts recommending between -$0.88 and -$3.32.
Revenue Estimates
It is expected that $90B in revenue will be generated in the current quarter, according to 10 analysts. It ranges from a high estimate of $34.1M to a low estimate of $17.44M. As of the current estimate, Syndax Pharmaceuticals Inc’s year-ago sales were $3.5MFor the next quarter, 10 analysts are estimating revenue of $33.46M. There is a high estimate of $43.6M for the next quarter, whereas the lowest estimate is $20.47M.
A total of 10 analysts have provided revenue estimates for SNDX’s current fiscal year. The highest revenue estimate was $154.2M, while the lowest revenue estimate was $83.05M, resulting in an average revenue estimate of $123.66M. In the same quarter a year ago, actual revenue was $23.68MBased on 10 analysts’ estimates, the company’s revenue will be $265.37M in the next fiscal year. The high estimate is $406.48M and the low estimate is $216.9M.
